Sodium Disorders Presentation............

sodium disorders

1. Sodium Disorders

2. Physiology of Sodium Homeostasis Role of Sodium: - Major extracellular cation - Maintains osmotic balance - Essential for nerve impulse transmission and muscle contraction .

3. Regulation Mechanisms: - Kidneys: Adjust sodium excretion/reabsorption. - Hormones: - Aldosterone: Promotes sodium reabsorption in kidneys. - Antidiuretic Hormone (ADH): Regulates water balance, impacting sodium concentration

4. Composition of Body Fluids Water Distribution : Comprises about 50% of body weight in women and 60% in men. Intracellular Fluid (ICF) : 55-75% of total body water. Extracellular Fluid (ECF) : 25-45% of total body water. Intravascular (plasma) and Extravascular (interstitial) spaces : Ratio of 1:3. Fluid Movement : Determined by Starling forces (capillary hydraulic pressure and colloid osmotic pressure).

5. Osmolality : Concentration of solutes in a fluid, expressed as milliosmoles per kilogram ( mOsm /kg). ECF vs. ICF : ECF mainly contains Na+ and anions (Cl−, HCO3−), while ICF contains K+ and phosphate esters. Tonicity : Effective osmolality determined by solutes restricted to a compartment (ECF or ICF).

6. Water Balance and Vasopressin (AVP) Maintenance of Osmolality : Between 280 and 295 mOsm /kg. AVP Secretion : Triggered by increases in osmolality above ~285 mOsm /kg. Thirst Mechanism : Activated at similar osmolality levels. Volume Modulation : Hypovolemia lowers the threshold for AVP release, while hypervolemia raises it. Renal Water Transport : Modulated by AVP via V2-type receptors in the kidney, affecting cyclic AMP and protein kinase A (PKA).

7. Renal Function and Sodium Homeostasis Sodium Reabsorption : Occurs throughout the nephron, mainly in the proximal tubule, thick ascending limb of Henle, distal convoluted tubule, and collecting duct. Regulation by Hormones : Angiotensin II, aldosterone, and sympathetic innervation promote Na+ reabsorption, while dopamine induces natriuresis. Principal Cells and ENaC : Aldosterone activates epithelial sodium channels (ENaC) in principal cells, increasing Na+ absorption and K+ excretion.

8. Water Homeostasis and Sodium Concentration Hyponatremia and Hypernatremia : Result from changes in the relative ratio of sodium to body water. Water Intake and AVP : These are the two primary factors in regulating serum osmolality. Hyponatremia : Often due to excess water intake or increased AVP (antidiuretic hormone) secretion. Hypernatremia : Typically caused by inadequate water intake or insufficient AVP activity.

9. Sodium Homeostasis and ECF Volume Sodium Balance : Abnormalities in sodium homeostasis lead to changes in extracellular fluid volume (ECFV) and circulatory integrity. Hypovolemia : Decreased ECFV, which can increase AVP release, causing water retention and potential hyponatremia. Hypervolemia : Increased ECFV, such as in heart failure or cirrhosis, also leads to increased AVP release due to arterial underfilling, contributing to water retention and hyponatremia.

10. Hyponatremia Hyponatremia is defined as a plasma sodium (Na+^++) concentration less than 135 mM. It is a common disorder, affecting up to 22% of hospitalized patients. The primary causes include increased levels of circulating antidiuretic hormone (AVP) and increased renal sensitivity to AVP, combined with the intake of free water. An exception to this is hyponatremia due to low solute intake.

11. Hyponatremia is categorized based on extracellular fluid volume (ECFV) into: Hypovolemic Hyponatremia Hypervolemic Hyponatremia Euvolemic Hyponatremia

12. Hypovolemic Hyponatremia Mechanism : Hypovolemia triggers neurohumoral activation, increasing AVP levels. AVP increases water reabsorption via renal V2 receptors, potentially causing hyponatremia when free water intake is increased.

13. Nonrenal Causes : Gastrointestinal losses (vomiting, diarrhea) Insensible losses (sweating, burns) Typically, urine Na+^++ concentration is <20 mM.

14. Renal Causes Primary Adrenal Insufficiency : Deficiency in aldosterone causing Na+^++ and water loss, leading to high urine Na+^++ concentration (>20 mM). Salt-Losing Nephropathies : Due to impaired renal tubular function (e.g., reflux nephropathy, interstitial nephropathies). Diuretics : Thiazides : Cause hyponatremia through volume depletion and polydipsia. Loop Diuretics : Less commonly cause hyponatremia, inhibit Na+^++-Cl−^-− and K+^++ absorption by the TALH. Osmotic Diuresis : Glycosuria, ketonuria, and bicarbonaturia . Cerebral Salt Wasting : A rare cause associated with intracranial disease.

15. Hypervolemic Hyponatremia Mechanism : Increase in total-body Na+^++-Cl−^-− with a proportionately greater increase in total-body water.

16. Causes : Edematous Disorders : CHF, cirrhosis, nephrotic syndrome. Renal Failure : Associated with increased urine Na+ concentration. Urine Na+ Concentration : Typically very low (<10 mM) in edematous disorders, except in cases of renal failure.

17. Euvolemic Hyponatremia Hypothyroidism : Moderate to severe hypothyroidism can cause hyponatremia, corrected with euthyroid state. Secondary Adrenal Insufficiency : Associated with predominant glucocorticoid deficiency.

18. Syndrome of Inappropriate Antidiuresis (SIAD) :Most common cause. Requires intake of free water at low serum osmolalities . Four patterns of AVP secretion: Unregulated, erratic AVP secretion. Failure to suppress AVP at lower osmolalities . "Reset osmostat " with a lower threshold osmolality. No detectable AVP, suggesting a gain in function in renal water reabsorption or a different antidiuretic substance.

19. Causes of SIAD :Pulmonary diseases (e.g., pneumonia). CNS diseases (e.g., tumors, meningitis). Malignancies (e.g., small-cell lung carcinoma). Drugs (e.g., SSRIs).

20. Low Solute Intake and Hyponatremia Mechanism : Occurs in patients with very low dietary solute intake, such as alcoholics consuming beer ("beer potomania") or individuals on extremely restricted diets. Urine Osmolality : Very low (<100–200 mOsm /kg) with urine Na+^++ concentration <10–20 mM.

21. Pathophysiology : Reduced urinary solute excretion limits water excretion, causing hyponatremia after modest polydipsia. AVP levels are typically suppressed or rapidly suppressible with saline hydration.

22. Assessment : Volume status must be evaluated alongside plasma Na+ concentration. Treatment : Depends on the underlying cause and volume status: Hypovolemic Hyponatremia : Often responds to saline therapy.

23. Hypervolemic Hyponatremia : Requires managing underlying conditions and limiting fluid intake. Euvolemic Hyponatremia : Treat the underlying cause (e.g., correcting thyroid or adrenal insufficiencies, managing SIAD).

24. Plasma Sodium Concentration : Does not directly indicate volume status. Volume Status Assessment : Essential for diagnosing and treating sodium disorders. Hypovolemic Hyponatremia : Characterized by low ECFV and high AVP levels. Hypervolemic Hyponatremia : Characterized by high ECFV (e.g., in heart failure) and high AVP levels despite perceived hypervolemia. Euvolemic Hyponatremia : Normal ECFV but high AVP due to non-osmotic stimuli such as syndrome of inappropriate antidiuretic hormone (SIADH).

25. Clinical features Pathophysiology: Cellular swelling due to water movement from hypotonic extracellular fluid (ECF) to intracellular fluid (ICF), causing cerebral edema. Symptoms: Primarily neurologic, including nausea, headache, vomiting, and potentially progressing to seizure, coma, and death. Complications: Normocapneic or hypercapneic respiratory failure, noncardiogenic pulmonary edema.

26. Causes of Acute Hyponatremia: Exercise-associated, iatrogenic (e.g., hypotonic IV fluids), recreational drugs (e.g., MDMA).

27. Chronic Hyponatremia: Results in efflux of organic osmolytes from brain cells, leading to reduced intracellular osmolality. Symptoms include nausea, confusion, seizures; increases risk of falls and fractures.

28. Osmotic Demyelination Syndrome (ODS): Risk with rapid correction (>8-10 mM in 24 h), affects brain regions (especially pons), leading to neurologic deficits.

29. Diagnostic Evaluation of Hyponatremia : Clinical Assessment: Evaluate volume status, underlying causes (e.g., drugs, illnesses). Imaging: Consider CT scan for CNS causes, chest X-ray for lung pathology. Laboratory Tests: Measure serum osmolality, urine electrolytes (Na+, K+), urine osmolality. Additional Tests: Thyroid, adrenal, pituitary function tests; serum glucose, uric acid levels.

30. Three Major Considerations in Hyponatremia Therapy: Symptom Severity and Urgency: Acute hyponatremia presents with severe symptoms (headache, seizures, coma), requiring urgent correction. Chronic hyponatremia (>48 hours) may have less severe symptoms but is at risk for osmotic demyelination syndrome (ODS) if corrected too rapidly.

31. Risk of Osmotic Demyelination Syndrome (ODS): Correction of plasma Na+ concentration by >8-10 mM in 24 hours or >18 mM in 48 hours increases risk. Requires cautious monitoring during corrective therapy.

32. Response to Interventions: Treatment focuses on correcting underlying causes: Euvolemic hyponatremia (e.g., SIAD) may respond to fluid restriction or pharmacologic therapy (e.g., vaptans). Hypovolemic hyponatremia responds to isotonic saline; cautious correction needed if chronic. Hypervolemic hyponatremia (e.g., CHF) improves with optimizing underlying condition (e.g., ACE inhibitors). Beer potomania responds to saline and dietary solute intake.

33. number of equations have been developed to estimate the required rate of hypertonic saline, which has an Na+ -Cl− concentration of 513 mM. The traditional approach is to calculate an Na+ deficit, Na+ deficit = 0.6 × body weight × (target plasma Na+ concentration – starting plasma Na+ concentration), followed by a calculation of the required rate.

34. Acute Symptomatic Hyponatremia: Hypertonic Saline: Rapidly increases plasma Na+ concentration (1-2 mM/h); monitor frequently due to unpredictable response. Supportive Care: Oxygen supplementation and ventilatory support for respiratory complications.

35. Correction Rate in Chronic Hyponatremia: Slow correction (<6-8 mM in first 24 hours) to prevent ODS; adjust based on patient risk factors. Reversal strategies include DDAVP and D5W for overcorrection prevention

36. Fluid Restriction: Effective for SIAD, challenging due to patient tolerance; urine-to-plasma electrolyte ratio guides intensity. Potassium Replacement: Corrects hyponatremia in hypokalemic patients; monitor for overcorrection risk. Increased Solute Intake: Oral salt tablets and urea preparations increase solute excretion, aiding in free water clearance.

37. Diuretics: Used in combination with salt tablets (e.g., furosemide) for SIAD; monitor for hypokalemia. Vaptans: Effective in SIAD and hypervolemic hyponatremia; monitor for liver function abnormalities (e.g., tolvaptan).

38. Hypernatremia Definition: Plasma Na+ concentration >145 mM. Incidence and Mortality: Less common than hyponatremia but associated with high mortality rates (40-60%) due to severe underlying diseases.

39. Causes: Water and Electrolyte Deficit: Commonly due to water loss exceeding Na+ loss. Excessive Na+ Intake: Rarely due to iatrogenic causes like excessive hypertonic solutions

40. Risk Factors: Elderly: Reduced thirst sensation and limited access to fluids. Central Defect in Hypothalamic Function: Rare cases with decreased thirst and AVP secretion.

41. Mechanisms of Hypernatremia: Nonrenal Losses: Insensible losses (fever, exercise), diarrhea (osmotic vs. secretory). Renal Losses: Osmotic diuresis (hyperglycemia, urea), nephrogenic diabetes insipidus (AVP resistance).

42. Clinical Manifestations: Neurologic: Altered mental status (confusion to coma), potential for cerebral hemorrhage in acute cases. Muscular: Hypernatremic rhabdomyolysis due to osmotic damage to muscle membranes.

43. Chronic Adaptation: Brain cells adapt to chronic hypernatremia (>48 hours) by accumulating organic osmolytes, reducing neurologic sequelae. Pediatric patients are susceptible to cerebral edema during rapid correction of hypernatremia .

44. Diagnostic Approach: History and Examination: Assess thirst, polyuria, and possible sources of water loss (e.g., diarrhea). Laboratory Tests: Measure serum and urine osmolality, urine electrolytes, and AVP levels to determine underlying cause. Differentiation: Use DDAVP response and copeptin levels to distinguish between central and nephrogenic DI.

45. Treatment of Hypernatremia: Correct Underlying Cause: Identify and address causative factors such as medications, hyperglycemia, hypercalcemia, hypokalemia, or diarrhea.

46. Correction Rate: Chronic Hypernatremia (>48 hours): Correct slowly over 48 hours to avoid cerebral edema, aiming for a correction rate of no more than 10 mM/day. Acute Hypernatremia (<48 hours): If due to sodium loading, can be corrected more rapidly at a rate of 1 mM/h.

47. Fluid Replacement: Administer water orally, via nasogastric tube, or intravenously as 5% dextrose (D5W). Monitor blood glucose during D5W administration to prevent hyperglycemia.

48. Hypotonic Saline: Consider initial treatment with hypotonic saline solutions (1/4 or 1/2 normal saline) based on volume status and severity of hypernatremia. Calculation of Water Deficit: Use formulas to calculate daily water deficit and replenish accordingly, especially in cases of nephrogenic or central diabetes insipidus (DI).

49. Additional Therapies: Central DI: Use DDAVP (desmopressin) via intravenous, intranasal, or oral routes to manage polyuria. NDI due to Lithium: Consider amiloride to reduce polyuria by inhibiting ENaC, reducing lithium entry into principal cells. Thiazides: May help reduce polyuria in NDI by inducing hypovolemia and enhancing proximal tubular water reabsorption. NSAIDs: Occasionally used to mitigate prostaglandin-mediated effects on urinary concentrating mechanisms in NDI, but with risks of gastric and renal toxicity.

50. Chronic Management: Thiazides, amiloride, and NSAIDs are reserved for chronic management of polyuria in NDI and not for acute hypernatremia management.

51. Clinical Scenario: Patient: 80-year-old male is brought to the emergency department by his family, who report that he has been confused and lethargic for the past two days. He has a history of dementia and was recently found to have been drinking very little water. On examination, he is tachycardic (heart rate 100 bpm), hypotensive (blood pressure 85/55 mmHg), with dry mucous membranes and decreased skin turgor. Labs: Serum sodium 155 mEq /L, BUN 50 mg/dL, creatinine 2.0 mg/dL.

52. Clinical Scenario: Patient: 60-year-old male presents with confusion, headache, and recent onset of nausea. He has a history of small cell lung cancer, which is known to be associated with SIADH. On examination, he is euvolemic with no signs of dehydration or fluid overload. Labs: Serum sodium 122 mEq /L, serum osmolality 260 mOsm /kg, urine osmolality 550 mOsm /kg, urine sodium 40 mEq /L.

53. Clinical Scenario: Patient: 70-year presents with worsening shortness of breath, swelling in her legs, and weight gain over the past two weeks. She has a history of congestive heart failure. On examination, she has bilateral pitting edema, jugular venous distention, and rales in both lung fields. Labs: Serum sodium 128 mEq /L, BUN 30 mg/dL, creatinine 1.2 mg/dL.

54. Clinical Scenario: Patient: 80-year-old is brought to the emergency department by his family, who report that he has been confused and lethargic for the past two days. He has a history of dementia and was recently found to have been drinking very little water. On examination, he is tachycardic (heart rate 100 bpm), hypotensive (blood pressure 85/55 mmHg), with dry mucous membranes and decreased skin turgor. Labs: Serum sodium 155 mEq /L, BUN 50 mg/dL, creatinine 2.0 mg/dL.

55. Thank You